Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors

Neoplasia (United States)

Volumn 14, Issue 8, 2012, Pages 670-677

  Ahsan, Aarif ^a   Ramanand, Susmita G ^a   Whitehead, Christopher ^b   Hiniker, Susan M ^a   Rehemtulla, Alnawaz ^a   Pratt, William B ^b   Jolly, Shruti ^a   Gouveia, Christopher ^c   Truong, Kristy ^c   Van Waes, Carter ^c   Ray, Dipankar ^a   Lawrence, Theodore S ^a   Nyati, Mukesh K ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AT 13387; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84865263433     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12986     Document Type: Article

References (37)

1. Doody JF, Wang Y, Patel SN, Joynes C, Lee SP, Gerlak J, Rolser RL, Li Y, Steiner P, Bassi R, et al. (2007). Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non-small cell lung cancers. Mol Cancer Ther 6, 2642-2651.
2. Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, and Solit DB (2008). Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 68, 589-596.
3. Burtness B (2005). The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 5, 1085-1093.
4. Ray D, Ahsan A, Helman A, Chen G, Hegde A, Gurjar SR, Zhao L, Kiyokawa H, Beer DG, Lawrence TS, et al. (2011). Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2. Neoplasia 13, 570-578.
5. Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, et al. (2011). Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res 17, 5755-5764.
6. Ahsan A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, Helman A, Menawat R, Bhojani MS, Lawrence TS, and Nyati MK (2010). Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res 70, 2862-2869.
7. Ahsan A, Hiniker SM, Davis MA, Lawrence TS, and Nyati MK (2009). Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitiza-tion. Cancer Res 69, 5108-5114.
8. Feng FY, Lopez CA, Normolle DP, Varambally S, Li X, Chun PY, Davis MA, Lawrence TS, and Nyati MK (2007). Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radio-chemotherapy in vivo. Clin Cancer Res 13, 2512-2518.
9. Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X, Davis MA, Chinnaiyan AM, Lawrence TS, and Nyati MK (2007). Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Onco-gene 26, 3431-3439.
10. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, and Yarden Y (1998). c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 12, 3663-3674.
11. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, et al. (1999). Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4, 1029-1040.
12. Huang Y, Kim SO, Jiang J, and Frank SJ (2003). Growth hormone-induced phos-phorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling. J Biol Chem 278, 18902-18913.
13. Neckers L, Mollapour M, and Tsutsumi S (2009). The complex dance of the molecular chaperone Hsp90. Trends Biochem Sci 34, 223-226.
14. Workman P (2004). Altered states: selectively drugging the Hsp90 cancer chap-erone. Trends Mol Med 10, 47-51.
15. Yang S, Qu S, Perez-Tores M, Sawai A, Rosen N, Solit DB, and Arteaga CL (2006). Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res 66, 6990-6997.
16. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA, et al. (2008). Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 68, 5827-5838.
17. Lavictoire SJ, Parolin DAE, Klimowicz AC, Kelly JF, and Lorimer IAJ (2003). Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem 278, 5292-5299.
18. Nyati MK, Maheshwari D, Hanasoge S, Sreekumar A, Rynkiewicz SD, Chinnaiyan AM, Leopold WR, Ethier SP, and Lawrence TS (2004). Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 10, 691-700.
19. Graham B, Curry J, Smyth T, Fazal L, Feltell R, Harada I, Coyle J, Williams B, Reule M, Angove H, et al. (2012). The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer. Cancer Sci 103, 522-527.
20. Woodhead AJ, Angove H, Carr MG, Chessari G, Congreve M, Coyle JE, Cosme J, Graham B, Day PJ, Downham R, et al. (2010). Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois oindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 53, 5956-5969.
21. Xu WP, Mimnaugh E, Rosser MFN, Nicchitta C, Marcu M, Yarden Y, and Neckers L (2001). Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276, 3702-3708.
22. Pratt WB and Toft DO (1997). Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18, 306-360.
23. Xu WP, Yuan XT, Xiang ZX, Mimnaugh E, Marcu M, and Neckers L (2005). Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat Struct Mol Biol 12, 120-126.
24. Wada T, Qian XL, and Greene MI (1990). Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61, 1339-1347.
25. Citri A, Kochupurakkal BS, and Yarden Y (2004). The Achilles heel of ErbB-2/ HER2-regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3, 51-60.
26. Sittler A, Lurz R, Lueder G, Priller J, Hayer-Hartl MK, Hartl FU, Lehrach H, and Wanker EE (2001). Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum Mol Genet 10, 1307-1315.
27. Modjtahedi H and Essapen S (2009). Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 20, 851-855.
28. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, and Hung MC (2008). Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13, 385-393.
29. Sakagami M, Morrison P, and Welch WJ (1999). Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases. Cell Stress Chaperones 4, 19-28.
30. Citri A, Harari D, Shohat G, Ramakrishnan P, Gan J, Lavi S, Eisenstein M, Kimchi A, Wallach D, Pietrokovski S, et al. (2006). Hsp90 recognizes a common surface on client kinases. J Biol Chem 281, 14361-14369.
31. Pratt WB, Morishima Y, and Osawa Y (2008). The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J Biol Chem 283, 22885-22889.
32. Citri A, Gan J, Mosesson Y, Vereb G, Szollosi J, and Yarden Y (2004). Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep 5, 1165-1170.
33. Sidera K, Gaitanou M, Stellas D, Matsas R, and Patsavoudi E (2008). A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 283, 2031-2041.
34. Dote H, Cerna D, Burgan WE, Camphausen K, and Tofilon PJ (2005). ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. Cancer Res 65, 6967-6975.
35. Neckers L and Workman P (2012). Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18, 64-76.
36. Ferrarini M, Heltai S, Zocchi MR, and Rugarli C (1992). Unusual expression and localization of heat-shock proteins in human tumor-cells. Int J Cancer 51, 613-619.
37. TrepelJ, Mollapour M,GiacconeG, and Neckers L (2010). Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10, 537-549.